Does TRICARE Cover Repatha (Evolocumab)? Coverage, Prior Auth, and Appeals Explained

What TRICARE Actually Covers for Repatha

TRICARE covers evolocumab (Repatha) when a beneficiary carries a diagnosis of established ASCVD or familial hypercholesterolemia and has failed to reach their LDL-C goal on optimized oral therapy. Coverage is not automatic. The drug sits on a non-preferred specialty tier and requires prior authorization through the beneficiary's regional managed-care support contractor (Humana Military for the East, Health Net Federal Services for the West, or the international SOS contractor). Without authorization, the pharmacy claim will reject at point of sale.

The clinical rationale for coverage is well-supported. FOURIER (N=27,564) demonstrated that adding evolocumab 140 mg every two weeks to background statin therapy reduced the composite primary endpoint of cardiovascular death, MI, stroke, coronary revascularization, or unstable angina by 15% relative to placebo over a median of 26 months (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) [1]. That level of evidence places PCSK9 inhibitors firmly in ACC/AHA guideline recommendations for high-risk patients who remain above LDL-C thresholds despite statins [2].

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy." [2] TRICARE's medical policy largely mirrors this language.

Prior Authorization Criteria for Repatha on TRICARE

Getting a prior authorization approved requires satisfying three documentation pillars: a qualifying diagnosis, proof of statin failure or intolerance, and an LDL-C value above the program's threshold.

Qualifying diagnoses. TRICARE generally authorizes evolocumab for (1) heterozygous familial hypercholesterolemia (HeFH), (2) homozygous familial hypercholesterolemia (HoFH), or (3) established clinical ASCVD, defined as a history of acute coronary syndrome, MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral artery disease with ABI <0.90 [3].

Statin optimization requirement. The prescribing provider must document that the patient has been on a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 90 days, or that a documented intolerance prevented titration [4]. Statin intolerance is defined broadly in the literature as myalgia, myopathy, or hepatotoxicity confirmed on at least two separate statins at any dose [5].

Ezetimibe step therapy. Most TRICARE regional contractors add a second step: failure or intolerance of ezetimibe 10 mg. Ezetimibe is inexpensive (under $20 per month generic), appears on TRICARE's Tier 1 formulary, and reduces LDL-C by an additional 18 to 20% when added to a statin [6]. Skipping this step is the single most common reason for a first-pass PA denial.

LDL-C threshold. The contractor typically requires a recent fasting lipid panel (drawn within the past six months) showing LDL-C at or above 70 mg/dL for established ASCVD patients or at or above 100 mg/dL for FH patients without additional very-high-risk features [2].

A 2023 analysis of PCSK9 inhibitor prior authorization patterns across large insurers found that incomplete documentation of statin intolerance or missing ezetimibe trial records accounted for 61% of initial denials [7]. Getting those two items into the chart before submission cuts the back-and-forth substantially.

Step Therapy: What TRICARE Requires Before Approving Repatha

Step therapy is mandatory. TRICARE follows a sequenced approach that generally looks like this: high-intensity statin first, ezetimibe added second if LDL-C remains above goal, and then PCSK9 inhibitor authorized third if the combination still leaves the patient above threshold.

There is a narrow exception for homozygous FH. Because HoFH involves severely dysfunctional or absent LDL receptors, statins alone produce minimal response. The FDA approved evolocumab specifically for HoFH in 2015, and the prescribing information notes that monotherapy with evolocumab 420 mg monthly reduced LDL-C by 30% in HoFH patients who were on background lipid-lowering therapy [8]. TRICARE contractors generally allow a shorter or waived statin-optimization requirement when the HoFH diagnosis is confirmed by genetic testing or clinical criteria (two first-degree relatives with LDL-C above 500 mg/dL, or the Simon Broome criteria) [9].

For established ASCVD without FH, there is no waiver pathway for the statin and ezetimibe steps unless the patient has documented, recurrent, and confirmed intolerance. A single complaint of muscle aches without a confirmed CK elevation or a rechallenge trial will not satisfy most reviewers. The provider's note should include: date of statin initiation, dose attempted, symptom onset timeline, CK value at time of symptoms, and outcome after dose reduction or drug switch [5].

The ACC has published a statin intolerance algorithm that can serve as a documentation template and is freely available through the AHA/ACC cardiovascular care portal [10]. Using that framework when writing the PA letter makes the intolerance narrative much harder to reject on technical grounds.

How to Submit the Prior Authorization and What to Include

Submitting a clean PA the first time saves weeks. The prescribing provider submits through the regional contractor's online portal or by fax. Required elements across most TRICARE contracts include:

The diagnosis code (ICD-10 E78.01 for HeFH, E78.02 for HoFH, or the appropriate ASCVD code such as I25.10 for chronic ischemic heart disease), the current and historical LDL-C values with lab dates, a list of all lipid-lowering agents tried with start/stop dates and doses, the reason each prior agent was stopped or was inadequate, the prescribing cardiologist's or endocrinologist's contact information, and the requested dose and frequency (140 mg every two weeks or 420 mg monthly) [8].

TRICARE contractors have up to 14 days to render a standard PA decision and 72 hours for urgent cases under federal managed-care timelines [11]. If the provider marks the request urgent due to recent ACS, a faster turnaround is expected by regulation.

What Happens After a Denial: The TRICARE Appeal Process

A denial is not final. TRICARE has a formal multi-step appeal process, and roughly 40 to 50% of initially denied specialty drug PAs are overturned on first appeal when additional clinical documentation is provided [12].

Step 1: Informal reconsideration. The provider contacts the managed-care support contractor directly, usually within 30 days of the denial letter. This is the fastest path and can be resolved by phone or portal upload if the denial was purely documentary (for example, a missing lab value).

Step 2: Formal appeal to the contractor. If reconsideration fails, the beneficiary or provider submits a written formal appeal. The letter should address every criterion cited in the denial reason and attach peer-reviewed literature supporting use. Citing FOURIER [1] and the 2018 ACC/AHA guideline [2] explicitly in the appeal letter gives the medical reviewer a clear evidence base to work from.

Step 3: Independent medical review. If the contractor upholds the denial, the case can be escalated to an independent external review organization. Under 32 CFR Part 199, TRICARE beneficiaries have the right to an external clinical review when a coverage dispute involves medical necessity [13].

Step 4: Grievance to the Defense Health Agency. The Defense Health Agency (DHA) serves as the final administrative authority for TRICARE coverage disputes. A formal grievance to DHA is the last internal step before any legal challenge [14].

Timeliness matters. Missing the appeal window (typically 90 days from the denial date) forfeits the right to that appeal level. The denial letter should state the exact deadline; if it does not, call the contractor and get the date in writing.

What TRICARE Pays and What the Beneficiary Pays

Under TRICARE Prime, specialty drugs like evolocumab filled at a TRICARE-network retail pharmacy carry a cost-share that depends on the beneficiary's status. Active-duty service members pay nothing for covered formulary drugs. Retirees and their dependents under Prime typically pay a fixed specialty copay, which as of 2024 runs $48 to $60 for a 30-day supply of a Tier 3 or Tier 4 drug when filled at a network pharmacy [15]. Filling through TRICARE Pharmacy Home Delivery (Express Scripts) for a 90-day supply reduces the per-dose cost further.

Under TRICARE Select, cost-sharing is a percentage of the allowed charge rather than a flat copay. For non-preferred specialty drugs, that percentage can reach 20 to 25% after the deductible, which on a drug with a list price near $580 per month translates to a meaningful out-of-pocket amount [15].

Out-of-network fills trigger much higher cost-sharing and should be avoided unless no network option exists within a reasonable distance.

The Manufacturer Savings Card: Why It Does Not Work for TRICARE Beneficiaries

Amgen offers a co-pay savings card for Repatha that can reduce commercial-insurance cost-sharing to as little as $0 per month for eligible patients. TRICARE beneficiaries cannot use it. Federal anti-kickback statutes and TRICARE regulations prohibit the use of manufacturer discount programs for beneficiaries enrolled in any federal health care program, including TRICARE, Medicare, Medicaid, and the VA [16].

Attempting to use the card anyway and then billing TRICARE for the balance constitutes a federal compliance violation. Providers who recommend the card to TRICARE patients without that caveat expose both the patient and their practice to risk.

Patients who face high out-of-pocket costs should instead ask the prescribing provider to document medical necessity thoroughly for the appeal record, request the 90-day supply through Express Scripts to reduce per-unit cost, and ask Amgen about the Repatha patient assistance program (Amgen Safety Net Foundation), which is separate from the commercial savings card and does not involve TRICARE billing [17].

LDL-C Targets That Justify Coverage: The Clinical Context

Understanding what LDL-C number triggers coverage eligibility helps providers time the PA submission correctly.

For very-high-risk ASCVD patients (defined as two or more major ASCVD events, or one major event plus two or more high-risk conditions), the 2018 ACC/AHA guideline places the LDL-C threshold for considering a PCSK9 inhibitor at 70 mg/dL on maximally tolerated statin plus ezetimibe [2]. A 2022 consensus statement from the National Lipid Association similarly recommends an LDL-C threshold of 55 mg/dL as the optimal goal for very-high-risk patients, noting that further reduction below 55 mg/dL is associated with additional event reduction without a safety signal [18].

FOURIER enrolled patients with established ASCVD and LDL-C of 70 mg/dL or higher on background statin therapy. Evolocumab reduced LDL-C by a median of 59% from baseline, bringing median on-treatment LDL-C to approximately 30 mg/dL [1]. No excess in adverse events including neurocognitive effects or new-onset diabetes was observed in the trial, which was consistent with the EBBINGHAUS sub-study (N=1,974) that specifically evaluated cognitive function [19].

The GLAGOV trial (N=968) showed that adding evolocumab to statin therapy produced statistically significant regression of coronary atherosclerosis as measured by intravascular ultrasound over 76 weeks (mean percent atheroma volume change -0.95% vs. +0.05% with placebo, P<0.001) [20]. That plaque-regression data strengthens the medical-necessity argument in PA submissions for high-risk patients.

Repatha vs. Alirocumab: Does TRICARE Prefer One Over the Other?

TRICARE does not universally prefer evolocumab over alirocumab (Praluent), and the two drugs are generally interchangeable from a formulary-management standpoint, though regional contract differences exist. Both are PCSK9 inhibitors approved for the same ASCVD and FH indications, and both require prior authorization [21].

Alirocumab at 75 to 150 mg every two weeks demonstrated a 15% relative reduction in major adverse cardiovascular events in the ODYSSEY OUTCOMES trial (N=18,924) among post-ACS patients on high-intensity statin therapy (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) [22]. The cardiovascular event-reduction data for both agents are essentially equivalent.

If a provider submits a PA for evolocumab and the contractor suggests alirocumab as an alternative, the prescriber is not obligated to switch. A documented clinical rationale for the specific agent (for example, the patient's preference for a monthly vs. biweekly injection schedule with the 420 mg autoinjector) can support preferring one agent.

The monthly 420 mg Pushtronex on-body infusor for evolocumab may be a meaningful differentiator for patients who prefer less frequent dosing, and that preference can be noted in the PA submission [8].

Monitoring Requirements After TRICARE Approves Repatha

Approval is typically granted for 12 months with an annual reauthorization requirement. The reauthorization should include a repeat fasting lipid panel showing the achieved LDL-C, documentation of tolerability, and confirmation that the underlying diagnosis has not changed.

If the achieved LDL-C on evolocumab falls below 25 mg/dL, some contractors will flag the case for clinical review, though no guideline recommends discontinuation based on very low LDL-C alone [2]. The FDA prescribing label does not specify a lower LDL-C limit for discontinuation, and FOURIER followed patients to LDL-C levels well below 20 mg/dL without a safety signal [1].

Injection-site reactions occur in approximately 3.2% of patients on evolocumab vs. 3.0% with placebo in the FOURIER trial, making them statistically indistinguishable from the placebo rate [1]. Providers documenting intolerance claims during reauthorization should rely on objective findings rather than injection-site complaints alone.

Annual reauthorization submissions that include the updated lipid panel, a brief clinical note confirming ASCVD status, and a statement that the patient is tolerating the medication well are rarely denied once initial authorization has been granted.